Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Solvay's Androgel REMS Proposal May Need More Restrictions - Cmte.

Executive Summary

Solvay may need a more restrictive Risk Evaluation and Mitigation Strategy for AndroGel 1% to adequately warn against the danger of secondary transfer of the testosterone gel, according to some members of FDA's Pediatric Advisory Committee

You may also be interested in...



Testimonials Lead To Overbroad Claims, DDMAC Warning Letter Says

Implied efficacy claims from a physician and patients for Testopel testosterone pellets, among many other problems with a series of promotional pieces, draw a warning letter to Slate Pharmaceuticals.

Testimonials Lead To Overbroad Claims, DDMAC Warning Letter Says

Implied efficacy claims from a physician and patients for Testopel testosterone pellets, among many other problems with a series of promotional pieces, draw a warning letter to Slate Pharmaceuticals.

Testosterone Gel Makers Brace For REMS, Black Box Warning

Risks of skin contact with children and women were known, but severity of adverse events took the field by surprise.

Related Content

Topics

UsernamePublicRestriction

Register

PS051222

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel